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Color vision is considered a marker of cone function and its assessment in patients with
retinal pathology is complementary to the assessments of spatial vision [best-corrected
visual acuity (BCVA)] and contrast detection (perimetry). Rod-cone and chorioretinal
dystrophies—such as choroideremia—typically cause alterations to color vision, making
its assessment a potential outcome measure in clinical trials. However, clinical evaluation
of color vision may be compromised by pathological changes to spatial vision and the
visual field. The low vision Cambridge Color Test (lvCCT) was developed specifically
to address these latter issues. We used the trivector version of the lvCCT to quantify
color discrimination in a cohort of 53 patients with choroideremia. This test enables
rapid and precise characterization of color discrimination along protan, deutan, and
tritan axes more reliably than the historically preferred test for clinical trials, namely the
Farnsworth Munsell 100 Hue test. The lvCCT demonstrates that color vision defects—
particularly along the tritan axis—are seen early in choroideremia, and that this occurs
independent of changes in visual acuity, pattern electroretinography and ellipsoid zone
area on optical coherence tomography (OCT). We argue that the selective loss of tritan
color discrimination can be explained by our current understanding of the machinery of
color vision and the pathophysiology of choroideremia.
Keywords: color vision, choroideremia, cones, retinal degeneration, ellipsoid zone, pattern electroretinogram,
Cambridge color test
INTRODUCTION
The primary retinal neurons for conscious vision are duplex, consisting of two broad types: the
rods and the cones (intrinsically photosensitive retinal ganglion cells—ipRGCs—which primarily
drive circadian function and the pupillary light reflex are not considered further in this paper). In
the healthy retina, rods confer scotopic (nocturnal) function; whilst cones are primarily used for
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photopic (daylight level) function. Although the cones are
present throughout the retina, their high density in the fovea is
responsible for high spatial resolution in normal subjects, which
is measured clinically by best-corrected visual acuity (BCVA),
which in turn provides a functional metric for foveal cones.
Spectral discrimination (color vision) is another key function of
cone-based vision, and it can be used to monitor cone function in
retinal pathology.
The physiological basis of trichromatic color vision is the
cone photoreceptor, which has three sub-types: the long- (L-),
medium- (M-), and short- (S-)wavelength sensitive cones. These
have spectral sensitivities with peaks at around 558 (L-cones),
531 (M-cones), and 419 nm (S-cones) (Dartnall et al., 1983). The
signal from any individual cone varies in only one dimension
and therefore cannot alone convey information regarding color
(univariance). The visual system extracts information about the
spectral quality of light by comparing the activity of the three
classes of cone, a process that commences in the second-order
retinal neurons, the bipolar cells (Solomon and Lennie, 2007;
Simunovic, 2016). Early post-receptoral processing is proposed to
occur in two molecularly, anatomically and functionally distinct
subsystems of color vision (Solomon and Lennie, 2007). The first,
phylogenetically ancient subsystem, compares quantal catches
from the S-cones to those of the M + L-cones (tritan color
discrimination). The S-cone system has poor spatial and temporal
resolution, and does not normally contribute significantly to
clinical measures of visual acuity (Solomon and Lennie, 2007).
The second, more recent sub-system, compares quantal catches
from the M- vs. L-cones (red-green color discrimination). Of
note, the latter is proposed to have evolved from a mechanism
specialized for extracting spatial detail from the visual scene
(Mollon, 1999). Thus reductions in visual acuity caused by retinal
pathology are often accompanied by acquired red-green color
deficiency, whilst acquired tritan deficiency may occur in the
presence of normal visual acuity (Simunovic, 2016).
Choroideremia is an X-linked chorioretinal dystrophy with
a prevalence of 1 in 50,000 which is caused by mutations in
the gene encoding Rab Escort Protein 1 (REP1). Patients with
choroideremia have progressive centripetal loss of retinal and
choroidal structure and typically have normal visual acuity until
their fourth of fifth decade. REP1 is expressed in all retinal cell
types, including in cones; however, choroideremia preferentially
affects the rods. The differential effects of choroideremia on the
rods is believed to reflect their greater dependence (compared
to the cones) on normal RPE function, which is compromised
early in the disease process (MacDonald et al., 2005, 2009). The
rods, in turn, appear to have a role in cone survival through
the secretion of trophic factors that have a protective effect
on cones. The absence of these factors is thought to be the
cause of secondary cone degeneration in rod-cone dystrophies,
and this is exemplified by experiments demonstrating that
transplantation of normal rods improves cone survival in models
of inherited retinal degeneration (Mohand-Said et al., 2000). One
key trophic factor has been termed “rod-derived cone viability
factor” (RdCVF) (Sahel and Léveillard, 2018), a thioredoxin-
like protein which is not produced by defective rods (Narayan
et al., 2016). Although other mechanisms have been proposed for
bystander cone degeneration, RdCVF appears to be a key player,
and has been used in preclinical gene therapy studies to delay
secondary cone loss (Byrne et al., 2015).
Anecdotally, choroideremia patients in the Phase I/II trials
of sub-retinal gene therapy reported improvements in color
saturation following treatment, suggesting that color vision may
be a possible biomarker for functional rescue. Although color
vision deficiency has not historically been recognized as a feature
of choroideremia, it has more recently been demonstrated to
result in color vision defects early in the disease course. However,
this dyschromatopsia may be difficult to characterize with
standard clinical tests (Jolly et al., 2015; Heon et al., 2016), both
because of the demands they place on subjects, and because their
results cannot be directly related to changes in the machinery
of color vision.
Color vision can be examined using a number of different
tests: the choice of which depends upon the characteristics
of the subject, and the likely mechanism of color vision loss
(Dain, 2004). The preferred test of the US Food and Drug
Administration (FDA) for the investigation of acquired color
vision deficiency in clinical trials is the Farnsworth-Munsell 100
Hue (Figure 1A; Farnsworth, 1943), in part as a result of its
longstanding use (Seitz et al., 2018). It consists of 85 colored
caps divided across four boxes that must be arranged in order
by the subject. The colored aperture of each cap subtends about
2 degrees at the recommended viewing distance, and their hues
are arranged by the subject so that they appear to form a gradual
progression in color. Each subject’s performance is quantified
using a scoring system, which is based upon the arrangement of
the caps. One drawback of the test is the large number of artefacts
introduced by the unequal perceptual steps between different
caps (Simunovic, 2016). Additionally, there is a high degree of
inherent test variability, making reliable quantitative analysis
difficult. As a consequence, large alterations are needed between
visits to establish genuine change (Kinnear and Sahraie, 2002).
The FM 100 Hue is particularly difficult for patients with visual
field loss to perform, as the task requires a significant portion
of visual search. Although many other color vision tests have
been developed, not all are suitable for patients with acquired
color vision deficiency (Simunovic, 2016). Fewer still are suited
to patients with severely impaired visual acuity or visual field.
The low vision Cambridge Color Test (lvCCT) was developed
especially to assess patients with acquired color vision deficiency
in whom spatial vision, or the visual field, is impaired. Loss of
color discrimination in the central visual field is not directly
influenced by peripheral visual field loss per se, though the latter
presents difficulties in the conduct of many tests of color vision—
as noted above, and demonstrated in Figure 1B (Swanson et al.,
1993; Jolly et al., 2015).
The lvCCT is a development of the standard version of the
CCT (Regan et al., 1994) (Figures 1C,D), which uses a Stilling-
type array, that in turn places high(er) demands on spatial
vision. The standard CCT has been used to investigate color
discrimination ellipses in choroideremia, and has demonstrated
evidence of preferential involvement of the tritan system of color
vision (Seitz et al., 2018). The standard CCT is demanding and
may not be suitable for all clinical trials participants with low
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vision or visual field loss (Seitz et al., 2018). Additionally, many
axes (i.e., ≥8) of color space are typically probed to derive
discrimination ellipses (Figure 1E), making this approach time-
consuming. As an alternative, testing time may be reduced by
simply assessing color discrimination along the so-called cardinal
axes of color space: the tritan, deutan and protan axes (the so-
called “trivector” test approach). The lvCCT (Figure 1D) has
been used in clinical trials aiming to restore cone function in
achromatopsia (Zein et al., 2014; Fischer et al., 2020). It can be
used in patients with poor visual acuity and reduced visual fields,
making it very useful for patients with retinal and visual pathway
pathology (Simunovic et al., 1998; Figure 1F).
We aimed to use the lvCCT trivector test to characterize
color vision loss in choroideremia, and to test its suitability as
a potential outcome measure in clinical trials. Patients with,
and without, significant loss of BCVA were tested: in particular,
we hypothesized that patients with well-preserved visual acuity
may still demonstrate tritan losses in color discrimination and
that loss of red-green color discrimination may ensue once
visual acuity was sub-normal (see above). Furthermore, we aimed
to compare the lvCCT findings with those obtained with the
currently preferred test of the US FDA, the FM 100-hue test.
Finally, we also aimed to compare color discrimination to other
estimates of macular function (electrodiagnostic assessment) and
structure [optical coherence tomography (OCT)].
MATERIALS AND METHODS
Patients were examined as part of the screening process to
assess eligibility for an ongoing retinal gene therapy trial for
choroideremia (NCT02407678). Control participants were
recruited from accompanying persons and staff members.
Informed consent was obtained and the work adhered to
the Declaration of Helsinki. All participants underwent
BCVA testing with a Bailey-Lovie style visual acuity chart
(Bailey and Lovie, 1976) and color vision testing with the
Metropsis System (Cambridge Research Systems, Cambridge,
United Kingdom). Individuals with visible media opacities, or
likely congenital color vision deficiency (failure at the Ishihara
test; N = 1) were excluded.
The control group was age-matched to the patients. Patients
were divided into two groups for analysis: preserved BCVA
(≥80 ETDRS letters) based on population studies defining the
upper limit of normal (Brown and Yap, 1995) and reduced
BCVA (<80 ETDRS letters) to explore the relationship between
BCVA and acquired color vision deficiency in choroideremia
(Simunovic, 2016). Examining patients with preserved BCVA
permitted investigation of the earliest defects in color vision.
Results for protan, deutan, and tritan axes were compared
between-groups using one-way ANOVA, following log
transformation. Additionally Spearman correlation of color
defect and BCVA was conducted.
The full cohort consisted of 21 control participants (mean
age 31 years; range 20–46 years), 35 choroideremia patients with
BCVA≥80 letters (equivalent to 0.10 logMAR, mean age 31 years;
range 14–55 years), and 18 choroideremia patients with reduced
BCVA (mean age 34 years; range 17–71 years). The subset of
30 patients that underwent additional testing had a mean age of
32 years (range 17–55 years), and all had a BCVA of ≥ 80 letters.
Summary statistics are shown in Table 1.
The trivector lvCCT was used to explore protan, deutan, and
tritan color discrimination with the white point of the test set to
the chromaticity co-ordinates of CIE D65 (u' = 0.209, v' = 0.488;
CIE (1976) u' v' co-ordinates) and the confusion point set to
protan (u' = 0.678, v' = 0.501), deutan (u' = -1.217, v' = 0.782)
and tritan (u' = 0.257, v' = 0.0). In this test, 4 discs subtending
4 degrees at a viewing distance of 1.5 m are presented to the
subject (see Figure 1D). The center of each disc is 4.3 degrees
from the center of the screen. Stimuli were presented for a
maximum of 20 s to allow participants adequate time to search
the display, even in the presence of severe visual field loss. An
auditory signal accompanied presentation of the stimulus to alert
patients and to draw attention to the screen. In order to negate
the possibility of subjects using perceived brightness differences
to detect differences in color, the lvCCT employs luminance
randomization: i.e., the four discs vary randomly in brightness.
One disc—the “test disc”—was varied systematically from the
remaining 3 (“background discs”) in chromaticity. The subject’s
task was to determine and then indicate which disc differed
from the remaining three in color via an attached button box.
Thresholds for protan, deutan and tritan axes were established
using an interleaved adaptive staircase procedure. Each staircase
involved a decrease rate of 50% in hue saturation before the first
reversal and a 12.5% decrease after the second reversal (fixed
increase rate of 25%). Threshold was calculated as the mean of the
final six, of a total of seven, reversals. If the subject was unable to
correctly determine the position of the most saturated test disc on
five consecutive occasions, testing along that axis was terminated
and the threshold set at the maximum saturation. Participants
undertook a training run before performing the actual test to
familiarize themselves with the task.
A subset of patients underwent both the FM 100 Hue and
lvCCT. The FM 100 Hue (DG Color, Wiltshire, United Kingdom)
was set at a viewing distance of 50 cm and took place within
a lighting cabinet approximating CIE standard illuminant D.
Caps were randomized by the examiner prior to testing, and
placed back in the tray. The participant was instructed to
arrange the caps in a gradual progression in color between the
fixed end caps. The order of the caps was recorded using the
accompanying custom software to calculate the total error score.
The tests were subsequently classified as normal or abnormal
based on published values (Kinnear and Sahraie, 2002), and
calculated values for the upper 95% confidence limit of normal
from the normative data collected above. Normative data for
the lvCCT test has been reported by Paramei and Oakley
(2014). Additionally, the reported variation across the age ranges
represented by our cohort is small. A kappa agreement between
tests was calculated.
The same patient subset also underwent ISCEV (International
Society for the Clinical Electrophysiology of Vision) pattern
electroretinogram (PERG) testing (Bach et al., 2013) with
both standard (15 degrees × 12 degrees) and large field (30
degrees× 24 degrees) checkerboard stimuli (Lenassi et al., 2012),
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FIGURE 1 | (A) Farnsworth-Munsell 100 Hue color vision test. (B) Simulation of visual field loss restricting the view of the test resulting in slow test times.
(C) Cambridge color test (CCT) target. (D) Low vision version of the CCT showing four circles across the screen, providing an easier target for patients with low
vision and reduced visual field. (E) Example output from full CCT version, producing an ellipse in color vision function in color space. (F) Example output from
trivector test showing outputs for the protan, deutan, and tritan axes.
TABLE 1 | Summary characteristics of patient groups.









Control 21 31 ± 6 91 ± 4.8 3.982 ± 2.353 4.559 ± 3.151 6.725 ± 2.467
Preserved BCVA 35 31 ± 9 86 ± 3.8 13.814 ± 20.334 9.872 ± 10.447 20.813 ± 27.983
Reduced BCVA 18 34 ± 15 72 ± 9.6 17.519 ± 19.946 14.401 ± 18.283 27.602 ± 25.803
Patient subset 30 32 ± 9 83 ± 5.4 3.453 ± 7.455 3.246 ± 6.114 6.673 ± 10.808
All data is presented as mean ± standard deviation.
using the P50 component as an objective measure of
suprathreshold cone-driven macular function and N95 as a
measure of retinal ganglion cell function. Recordings were
obtained using gold foil recording electrodes using a constant
check size of 0.8 degrees. Testing was performed using the
Espion system (Diagnosys LLC, Lowell, MA). The key features
of the PERG are P50 peak time and amplitude as markers of
macular dysfunction. Additionally, N95 is indicative of ganglion
cell dysfunction.
The color vision results for each axis were treated as Cartesian
co-ordinates in CIE (1976) u', v', and a combined vector
calculated with | | CV| | =
√
(((protan2 + deutan2)/2) + tritan2),
where | | CV| | is the absolute color vision vector length.
Protan and deutan results were averaged to reduce the impact
of weighting toward L/M defects. A Spearman regression model
examined the relationship between the PERG and the color vision
vector combining all axes.
In order to investigate possible structural correlations to
color discrimination, a custom program was written in the
R programming language (v3.6.3) (R.C. Team, 2017). Spectral
domain optical coherence tomography (SD-OCT) images were
acquired during screening using the Spectralis OCT volume
(Heidelberg Engineering, Heidelberg, Germany). Data were
exported as XML files and each OCT b-scan per patient
(Figure 2A) manually inspected to identify coordinates of the
limiting edges of the intact ellipsoid zone (EZ). These coordinates
were input into the custom program, resulting in a polygon
overlaid on the en-face image (Figure 2B) representing the area
of the ellipsoid zone across all B-scans in a volume. In difficult
cases where the ellipsoid zone termination was unclear, the
profile method detailed by Smith et al. (2019) was employed.
The relationship between EZ and color vision was examined
using Spearman’s rank-order correlation coefficients. EZ area
was utilized to order avoid the confounding effects of retinal
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FIGURE 2 | (A) Images on the left show the individual b-scan slices from an optical coherence tomography (OCT) volume with the central slice expanded. The green
arrows denote the edges of the ellipsoid zone. These co-ordinates from each of the slices are plotted on the infra-red image on the right (B) and connected to create
an ellipsoid area across the OCT volume.
remodeling on thickness measurements (Jolly et al., 2020). EZ is
a measure of remaining retina.
Groups were compared using a two way ANOVA. Due to
unequal variances, post hoc analysis was conducted with Games-
Howell comparisons. All results are reported for the right eye
only. All statistical analyses were conducted in SPSS (version 25.0,
IBM Software, New York, NY, United States) or GraphPad Prism
9 (GraphPad Software, San Diego, CA, United States) unless
stated otherwise.
RESULTS
Comparison Between Groups Shows
Early Tritan Loss
Figure 3 shows the spread of the raw lvCCT color discrimination
data, with the highest threshold along the tritan axis in all cohorts
as shown by the longest vector lines aligned with the vertical axis.
There was greater variation in color discrimination thresholds
in the choroideremia patients than the normal controls. Group
averages are shown in Figure 3B. There was a statistically
significant difference between groups, as determined by two-way
ANOVA for protan [F(2, 53) = 9.09, P < 0.01], deutan [F(2,
53) = 6.44, P < 0.01], and tritan [F(2, 53) = 19.54, P < 0.01]
thresholds. A Games-Howell post hoc test revealed that the color
discrimination was significantly worse in both the “preserved”
and reduced BCVA cohorts compared to the control group for
all three color confusion axes (P ≤ 0.05). However, the two
choroideremia cohorts were not significantly different for any of
the axes (P > 0.05). Figure 4A demonstrates the classification of
the color defect for each eye with choroideremia and shows that
a higher proportion had a tritan defect compared to classification
of a red-green defect.
The Spearman correlation co-efficient for BCVA and
combined red-green vector length and tritan vector length
was -0.59 (-1.1 to -0.12 95% confidence interval) and -0.46
(-0.92 to 0.001 95% confidence interval), respectively. This was
significantly for red-green (P = 0.02) but not for tritan (P = 0.05),
consistent with the change in a color defect independent to
BCVA (Figure 4B).
Comparison With 100 Hue Reveals the
Cambridge Color Test Is More Sensitive
The majority of patients demonstrated abnormal results on both
tests (Table 2). A clear axis of defect on the FM 100 Hue was not
evident in any of the eyes (representative test result for the 100
Hue and lvCCT for the same eye shown in Figure 5). Out of the
19 eyes classified as abnormal by the lvCCT, 26% were classified
as having a clear tritan defect, 11% as having a protan defect, 16%
as having a deutan defect and 47% as having a defect along two or
more axes. In all instances of the latter, tritan discrimination was
affected. The kappa agreement coefficient, k = 0.3878 (P = 0.03)
indicated only fair agreement between the FM 100 Hue and CCT.
No Correlation Between Color Vision and
Pattern Electroretinogram
In order to examine suprathreshold macular function objectively,
PERG was conducted on the subset that went additional testing
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FIGURE 3 | Summary of color discrimination results. Spread of individual data points plotted against protan, deutan, and tritan scores on the X, Y, and Z axes,
respectively (black dots). The circles on the axes walls show the corresponding shadows of the results on each axes separately. (A) Choroideremia eyes with
preserved BCVA. (B) Choroideremia eyes with reduced BCVA. (C) Control eyes. The higher the number, the greater the degree of the color defect against the
corresponding axis. (D) Pirate plot of group differences. The outer envelope shows the spread of the raw data with the widest point showing the mean and the black
line representing the median. The gray lines represent the interquartile range. Additionally, dots represent each raw data measurement point.
FIGURE 4 | (A) Classification of color vision defects (CVD) measured with the low vision Cambridge Color Test (lvCCT) with the regions of normal color vision, tritan
loss, red-green loss, and combined loss labeled. (B) Correlation of best-corrected visual acuity (BCVA) with red-green and tritan color defects. The vertical dotted
line shows 20/20 visual acuity. The blue and red lines show the upper 95% cutoff of normal for the tritan and red-green loss, respectively.
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TABLE 2 | Classification of eyes as normal or abnormal when tested with the 100
Hue and Cambridge Color Test (CCT).
lvCCT abnormal lvCCT normal
100 Hue abnormal 17 6
100 Hue normal 2 5
and had preserved BCVA eyes. In response to the standard
field PERG stimulus, the P50 and N95 were measurable in
26 out of 30 eyes, with the remaining 4 showing a flatline
response. Mean P50 peak time for the cohort was 56.4± 12.7 ms
with a mean P50 amplitude of 0.77 ± 0.49 µV. The mean
amplitudes were subnormal based on local reference ranges (x-x
ms and y-y µV, respectively) and the Espion normative database
(Lenassi et al., 2012). The N95 amplitude for the cohort was
1.89± 1.17 µm, suggesting a preserved N95:P50 ratio, indicating
preserved retinal ganglion cell function. The multiple regression
model demonstrated no significant relationship between any
of the PERG parameters with | | CV| | (R = 0.16, P = 0.90).
Coefficients were -0.14 [-7.4 to 7.1], P = 0.96 for P50 peak time,
43.0 [-284.4 to 198.4], P = 0.72 for P50 amplitude, and 32.0 [-65.8
to 129.8], P = 0.50 for N95 amplitude.
Optical Coherence Tomography Ellipsoid
Zone Area Does Not Correlate to Color
Discrimination
Thirty patients with choroideremia had OCT images from the
same day as color vision testing with sufficient quality to enable
qualitative delineation of the retinal layers. Measurement of the
ellipsoid area was performed using the process described in the
methods section. Images on which the ellipsoid zone could not
be reliably commented on were excluded from imaging analysis.
The color vector was plotted against the ellipsoid area (Figure 6)
and showed a negative trend. The slope of the regression line
indicated a reduction in color vector of -1.15 for each unit
reduction in ellipsoid area (95% confidence interval -2.59 to
0.29); the relationship was not statistically significant (P = 0.11).
The findings remained non-significant when each color axis was
measured separately.
DISCUSSION
This study uses color discrimination, as assessed by the lvCCT, to
characterize dyschromatopsia in 53 choroideremia patients, with
and without, significant loss of visual acuity. The results were
compared to those obtained using more established methods,
including the Farnsworth Munsell 100-Hue test and the ISCEV-
standard pattern ERG measure of macular function. The lvCCT
results were also compared with a spectral-domain OCT measure
of macular preservation, with an overall view to assess the
potential suitability of color discrimination as an outcome
measure in clinical trials.
The lvCCT rapidly characterized color discrimination (mean
testing time 5 min) along the cardinal axes of color space. By
contrast, the FM 100 Hue took longer to perform (over 30 min)
and provided results that could not directly be related to losses of
discrimination in either of the two subsystems of color vision (M
vs. L-cones, measured via protan and deutan axes, and S-cone vs.
FIGURE 5 | Representative sample of a test result for the same eye from the FM 100 Hue (A) and low vision Cambridge Color Test (lvCCT) (B). The FM 100 Hue
does not have a clearly definable axis of color loss, whereas the lvCCT results indicate a reduced tritan score (longer vector) but normal protan and deutan scores as
shown by the short vectors.
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FIGURE 6 | Regression relationship between color vector and ellipsoid area in
choroideremia. The color vector represents the degree of color vision loss
across the three axes with a higher number representing a greater degree of
color loss. The solid line is the regression line and 95% confidence intervals
are shown with the dotted lines.
M + L-cone, assessed via the tritan axis). Furthermore, the two
tests only demonstrated fair agreement.
The majority patients had tritan color defects, which is in
keeping with previous reports in rod-cone dystrophies (Swanson
et al., 1993; Seitz et al., 2018). The vectors in the S cone direction
could be compared to the L and M cone directions due to the
use of a normal control group, which allows the use of the
color vector | | CV| | to be used as a valid approach. All color
spaces include the assumption that just noticeable differences are
additive. There are several possibilities that should be considered
to account for this finding. Although cataract is a feature of some
retinal dystrophies, none of the included patients had significant
media opacity: hence absorption by lens pigment cannot account
for our observation. It has been previously noted that the S-cones
appear to be especially vulnerable to retinal pathology, and there
are several hypotheses which have attempted to account for
this observation (Mollon, 1982; Simunovic, 2016). Part of the
apparent vulnerability of S-cone mediated visual function to
pathology appears to arise from adaptational differences between
the S-cone mechanism and the M-/L-cone mechanism and
biases introduced by testing approaches. Mollon hypothesized
that certain tests (e.g., those employing yellow backgrounds)
may place the S-cone mechanism at disadvantage through
adaptation of post-receptoral mechanisms to one extreme of
their operational range. Such a hypothesis cannot be invoked to
explain our data, however, as neutral adaptation conditions were
used. However, adaptation asymmetries have also been identified
for neutral/white backgrounds (Kalloniatis and Harwerth, 1989;
Simunovic, 2016; Simunovic et al., 2021). In particular, the S-cone
mechanism is more likely to be probed under conditions where
it does not display Weber-like adaptation. This may lead to
apparent selective pathology through adaptational asymmetry
(Kalloniatis and Harwerth, 1989; Simunovic, 2016; Simunovic
et al., 2021); this asymmetry may account for at least part of
the apparent vulnerability of the S-cones. Another hypothesis—
the so-called “vulnerable photoreceptor” hypothesis—supposes
that the S-cones are inherently more susceptible to pathological
processes. For example, S-cones have been reported to be
more susceptible to metabolic damage (Hood and Greenstein,
1988). Furthermore, it has been suggested that S-cones may be
preferentially affected by rod-selective pathology. Part of this
shared “vulnerability” may be driven by physiological similarities
between the rods and the S-cones; for example, S-cones and
rods share similarities in distribution which may render them
similarly vulnerable to topographically variable pathological
processes (Curcio et al., 1991; Hofer et al., 2005). Furthermore,
S-cones and rods share similarities in the expression of certain
proteins, e.g., carbonic anhydrase (Nork et al., 1990), which may
place them under similar pathophysiological stress under certain
conditions. Furthermore, both S-cones and rods derive from a
common precursor cell, as evidenced by patients with Nr2E3
mutations, who have an increased S-cone complement, but a
grossly abnormal rod complement (Sohn et al., 2010). There is an
increase in the inflammatory response following rod death which
has a greater effect on S-cones compared to L- and M-cones (Di
Pierdomenico et al., 2020). Cone cells have access to an alternative
Mũller cell-mediated visual cycle, which reduces their reliance on
the RPE for chromophore recycling. Mũller cells have a lower
association with S-cones compared to other cone types, which
may make them more vulnerable RPE degeneration (Lindenau
et al., 2019) in choroideremia. In view of the differences between
S-cones and other cone types, and simultaneous similarities with
rods, it is possible that S-cones may be preferentially affected by
primary rod disease, either via inflammatory processes or other
degenerative processes.
Dyschromatopsia was evident prior to reductions in BCVA in
many choroideremia subjects; for this reason, it may prove to
be a suitable functional biomarker for very early abnormalities
in macular function. In choroideremia, foveal architecture is
observed to be disrupted before BCVA loss occurs (typically
retinal thickening with blunting of the foveal depression). This
in turn suggests that other aspects of visual function may
better reflect early macular pathology in choroideremia and
therefore highlights the importance of this work (Jacobson
et al., 2006). In particular, it has previously been noted that
tritan color vision deficiency typically occurs in patients with
well-preserved BCVA. It has been argued that this reflects
in part the underlying physiology of color processing. In
particular, the S-cones comprise only a small proportion of
the cone complement (about 4%) and their loss will not
affect spatial resolution (BCVA) in the majority of patients.
However, the M-/L-cone mechanism has been proposed to be
parasitic upon a pathway which initially evolved to extract
spatial detail (Mollon, 1999). For this reason, loss of M-/L-
cone mediated color discrimination is often seen in patients
who have concurrent loss of BCVA (Marré and Pinckers, 1985;
Simunovic, 2016).
All patients with choroideremia had an abnormal pattern
ERG P50 component, consistent with macular dysfunction,
including those with preserved BCVA. However, the severity
of the PERG reduction does not correlate with color
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discrimination at the lvCCT; this is in keeping with previous
findings (Falcao-Reis et al., 1991). PERG and psychophysical
measures of macular function have been reported to be
discordant, and this may reflect the different areas assessed
by the two modes of testing (Ciavarella et al., 1997). We
have previously demonstrated a relationship between color
vision defect with central microperimetry threshold (Jolly
et al., 2015). Microperimetry is likely reflective of cone
function in the area tested so is probably exploring a more
comparable cone population (Simunovic et al., 2016; Han
et al., 2018). Different functional measures test different aspects
of vision over different regions of the visual field so will not
necessarily show good correlation. Additionally, previous
work has shown autofluorescence area of preservation and
location in relation to the fovea appeared to play a role in
explaining color vision losses in choroideremia. This may
reflect the fact that more advanced FAF changes correlate
to decreased photoreceptor function/visual pigment cycling
(Jolly et al., 2015).
The OCT ellipsoid area was utilized as an indirect marker of
cone presence, and the direction and extent of association was
examined in relation to color discrimination. Although a negative
correlation was shown, this was not statistically significant.
Ellipsoid area in part reflects the disease stage, it may correlate
poorly to color discrimination for two reasons. First, if such
changes occur outside of the retinal areas probed by the lvCCT,
no correlation would be anticipated. Second, early functional
alterations in the cones may be indicated by changes other
than complete obliteration of the ellipsoid layer (e.g., fundus
autofluorescence).
In summary, tritan defects are seen early in choroideremia,
prior to BCVA loss. This finding is generally in keeping with
our current understanding of the machinery of color vision,
the known adaptational asymmetries in the S- and M-/L-cone
subsystems of color vision and the dependence of cones on
the rods for survival. We note that several patients who have
undergone sub-retinal AAV2.REP1 gene “replacement” therapy
have reported subjective improvements in color saturation
following surgery, which has prompted us to explore color
discrimination as part of an ongoing Phase 2 trial. Color vision
appears to be an early biomarker of macular dysfunction in
choroideremia and may be more sensitive than BCVA when
used for monitoring gene therapy outcomes. We note that other
approaches could be used to explore these subjective reports
in color vision. For example, patients with symmetrical vision
loss could undergo testing to assess inter-ocular differences
in perceived saturation following first-eye surgery. Where this
is not possible, exploration of white-points/long term color
constancy could be explored. Furthermore, changes in receptoral
function could be determined by assessing threshold-vs. intensity
functions pre-, and post-surgery, to elucidate changes in the S-,
M-, and L-cones as well as the rods. Such testing may also help to
identify the site of losses of sensitivity (i.e., d1/2, or receptoral vs.
d3, or post-receptoral), as previously outlined (Seiple et al., 1993;
Simunovic et al., 2021).
In summary, this study quantifies color vision deficits in
patients with choroideremia with both preserved and reduced
visual acuity, and reveals a high incidence of S-cone/tritan
pathway dysfunction. The lvCCT trivector test provides a rapid
means of quantifying color discrimination along the cardinal axes
of color space in this patient group. Furthermore, it identifies
losses in central macular function in patients prior to the loss
of visual acuity or evidence of structural change on OCT. This
highlights the potential use of color discrimination as an outcome
measure in future clinical trials which target sub-retinal gene
therapy to the macula.
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